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A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia caused by infection with severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) was successively reported in Wuhan, China. The major 
presentations of patients are fever, fatigue, and dry cough. No cases have been reported with night sweats as the 
first symptom. This article presents a case that was diagnosed with COVID-19 pneumonia with night sweats as 
the first symptom. Chest CT showed patches of ground-glass opacity, and qRT-PCR results of SARS-CoV-2 were 
positive. After treatment, the patient did not present with night sweats again, the chest CT showed that the 
ground-glass opacity was completely absorbed, and the SARS-CoV-2 nucleic acid test results were negative. This 
case suggests that night sweats might be the first and major symptom of COVID-19 pneumonia. 
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Introduction 
Since December 2019, a number of coronavirus disease 
2019 (COVID-19) pneumonia patients have been diagnosed 
in Wuhan, Hubei Province, China. With the spread of the 
epidemic[1], such cases have been found in other regions in 
China and abroad. Of the more than 3000,000 cases reported, 
the major presentations of patients are fever, fatigue, and dry 
cough. Other symptoms include nasal congestion, runny nose, 
and diarrhea. No cases have been reported with night sweats 
as the first symptom. This case study reports a patient 
diagnosed with COVID-19 pneumonia with night sweats as 
the first symptom. Night sweats ceased after 10 days of 
treatment (lopinavir and ritonavir tablets and recombinant 
human interferon alb), and a nucleic acid test results for the 
virus were sequentially negative twice. Thus, this is the first 
report of a patient diagnosed with COVID-19 pneumonia with 
night sweats as the first symptom. 
Case Description 
A 19-year-old young male patient diagnosed with COVID-
19 pneumonia was admitted to the hospital mainly because of 
night sweats. During his study in Wuhan, Hubei Province, the 
patient presented with night sweats for more than one month 
without obvious cause. No observations of fever, cough, 
expectoration, fatigue, poor appetite, emaciation, dyspnea, or 
other symptoms were reported [2-5]. On January 14, 2020, the 
patient returned to Guiding County, Guizhou Province, but 
still had night sweats. Because his father had previously 
suffered from tuberculosis, it was recommended that the 
patient undergo further examinations. Therefore, the patient  
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Table 1. Patient laboratory characteristics. 
 
#: The value in the patient was slightly increased. 
 
went to the People’s Hospital of Guiding County on January 
18, 2020. The medical staff were informed that the patient had 
returned from a COVID-19 pneumonia epidemic area. Chest 
CT showed patches of ground-glass opacity in the lateral basal 
segment of the lower lobe of the right lung (Fig. A), and an 
oropharyngeal swab was sent to the Centers for Disease 
Control (CDC) for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) testing. On the same day, the 
patient presented with fever (body temperature = 38°C). After 
physical cooling and rehydration treatments, his body 
temperature returned to normal. On January 19, 2020, the 
patient had intermittent night sweats. On January 20, 2020, the 
oropharyngeal swab test result for SARS-CoV-2 was negative. 
On the next day, another oropharyngeal swab was taken and 
submitted for examination. The result was positive for the 
virus. On January 22, 2020, it was submitted again to the CDC 
and reconfirmed to be positive. Physical examination 
indicated no redness or swelling in the pharynx. Bilateral lung 
percussion and auscultation indicated no obvious 
abnormalities. Auxiliary examination showed the complete 
blood count, C-reactive protein, procalcitonin, erythrocyte 
sedimentation rate, liver and kidney function, D-dimer, 
myocardial enzymology, and electrolyte levels were normal 
(Table 1). Therefore, the patient was diagnosed with COVID-
19 pneumonia. On January 23, 2020, the patient was treated 
with lopinavir and ritonavir tablets (2 tablets oral bid) and 
recombinant human interferon alb (50 μg atomization bid), 
and the night sweats disappeared after 2 days of treatment. For 
close isolation treatment, the patient was transferred to 
Guizhou Jiangjunshan Hospital (formerly Guiyang Public 
Health Treatment Center) on January 28, 2020. Treatment 
plans remained unchanged during the whole course. The 
nucleic acid test results for SARS-CoV-2 on February 1, 2020, 
were negative and were negative again the next day. Chest CT 
was normal on February 3, 2020. The patient was cured and 
discharged on February 5, 2020. 
Discussion 
According to a recent study [3] published in the Lancet, the 
most common symptoms at the onset of COVID-19 
pneumonia are fever (83%), cough (82%), and dyspnea (31%). 
Less common symptoms are muscle pain, headache, dizziness, 
chest pain, and diarrhea, accounting for less than 10% of  
4-10 4.15 4.95 4.19 4.08 5.64
4-5.5 4.67 9.23 5.01 5 4.99
2-7 2.3 6.72 2.07 2.09 3.32
0.80-4.00 1.12 1.93 1.7 1.54 1.88
120-160 145 157 158 155 152
132-150 159 143.2 141.8 142.1 —
3.5-5.3 4.16 3.95 4.33 4.95 —
96-108 102.5 101.2 98.7 100.5 —
5-40 11.5 27.2 7 8 11
8-40 18.1 18.2 23 19 21
35-55 49.2 53.2 51.8 50.1 47.6
53-123 81.5 82.3 95.8 87.8 68.1
5.1-20 14.5 18.2 13.4 18.9 18.6
0-0.3 0.83 — 0.05 — 0.008
0-190 — — 112 117 —
11-16 — 13.7 13.7 12.4 13.4
0-
Table 1.Clinical Laboratory Result.
Refer ence
RangeMeasure Hospital  Day 1 Hospital  Day 10 Hospital  Day 12 Hospital  Day 14 Hospital  Day 17
White-cell count( 10 /L   )
Red-cell count( 10 /L )
Absolute neutrophil count(10 /L )
























0-15 6 5 3
0-8 2.1 5.3 2.14
0-0.5 0.24 0.03 — — 0.027
83-100 — — 96.8 38.1
35-45 — — 36.3 39.4 83.2
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Figure 1. CT images of the chest in the lung window. (A) Chest CT on January 18, 2020, showed patches of ground-glass opacity in the lateral basal 
segment of the lower lobe of the right lung. (B) Chest CT on January 23, 2020, showed patches of ground-glass opacity in the lateral basal segment of 
the lower lobe of the right lung was decreasing. (C) Chest CT on January 26, 2020, showed patches of ground-glass opacity that decreased after 3 days 
of treatment. (D) Chest CT on February 3, 2020, showed that the ground-glass opacity was completely absorbed. 
 
patients. In addition, some studies [4,5] reported that fever, 
cough, and fatigue were the major clinical symptoms. 
Currently, there have been no reports that night sweats are the 
first and major symptom related to COVID-19 pneumonia. 
Night sweating refers to abnormal sweating after falling asleep 
and is characterized by sweating cessation after waking up. 
The etiology mainly includes infection, tumor, endocrine 
dyscrasia, and medication, of which tuberculosis is the main 
cause of night sweats in young patients. This patient was a 
young man whose father suffered from tuberculosis; therefore, 
he had a history of contact with tuberculosis. Accordingly, 
tuberculosis should be considered first. The erythrocyte 
sedimentation rate, purified protein derivative and interferon-
γ release assays were all negative; thus, tuberculosis was 
excluded. In addition, the patient’s history, physical signs, and 
other auxiliary examinations showed that the night sweats 
were less likely to be caused by other known diseases. 
The first and major symptom of the patient was mild night 
sweating, which lasted for more than one month. Complete 
blood count showed that leukocytes and lymphocytes were 
normal, and that the D-dimer and related infection indexes 
were normal. According to the characteristics of patients 
reported so far, the presentation of this patient does not 
conform to the clinical manifestations of COVID-19 
pneumonia. However, results from qRT-PCR analyses of 
oropharyngeal swabs from the patient for SARS-CoV-2 were 
positive. After treatment, the patient did not present with night 
sweats again, the chest CT showed that the ground-glass 
opacity was completely absorbed (Fig. 1D), and the SARS-
CoV-2 nucleic acid test result was negative. This case suggests 
that night sweats might be the first and major symptom of 
COVID-19 pneumonia. Clinicians should be alerted to 
pneumonia cases with night sweats and cases from epidemic 
areas to avoid misdiagnosis and missed diagnosis and to avoid 
the case developing into a potential infectious source.  
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